World Health Organization resumes coronavirus trial on malaria drug hydroxychloroquine after examining safety concerns – OrthoSpineNews

SaveSavedRemoved 0
Deal Score0
Deal Score0


June 3, 2020 / Berkeley Lovelace Jr., William Feuer

The World Health Organization is resuming its trial of hydroxychloroquine, the malaria drug backed by President Donald Trump to combat the deadly coronavirus, after temporarily halting research over safety concerns. 

The Data Safety Monitoring Board decided there was no reason to discontinue the international trial after reviewing available data on the drug, WHO Director-General Tedros Adhanom Ghebreyesus said during a press conference Wednesday at the agency’s Geneva headquarters.

“The executive group received this recommendation and endorsed the continuation of all arms of solidarity trial including hydroxychloroquine,” he said. 

On May 25, WHO announced it had temporarily suspended its trial of the drug over safety concerns. The announcement came days after a study published in medical journal The Lancet, which is now being reexamined, found that hospitalized Covid-19 patients treated with hydroxychloroquine had a higher risk of death than those who didn’t take it.

READ THE REST HERE

Print Friendly, PDF & Email





Source link

We will be happy to hear your thoughts

Leave a reply

Fight Back! Get the Latest in Products and Services to Keep Coronavirus Covid-19 Out Of Your Life!